GMP IPO
📋 Filings Intelligence
About Contact
LIVE - Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement - financial results, order wins, dividends, mergers and more. Updated live.

-
Filed today
-
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings -

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Shukra Pharmaceuticals Ltd

Shukra Medtech Q2 FY27 Net Profit Rs. 1,601.20 Lakhs, Revenue Rs. 4,220.38 Lakhs

RESULTS ▲ Positive Development MEDIUM RISK
📅 Filed on BSE: 04 Nov 2026, 08:44 PM IST  ·  BSE ID: 42aa3723-1619-4a17-bcc5-306869b775c2
View Original BSE Filing (PDF)
💡
In Simple Terms
The company, now Shukra Medtech, released its financial results showing profits of Rs. 1,601.20 Lakhs and revenue of Rs. 4,220.38 Lakhs.
🤖 AI Summary
  • Shukra Medtech reported standalone net profit of Rs. 1,601.20 Lakhs for Q2 FY27.
  • Revenue from operations stood at Rs. 4,220.38 Lakhs for the quarter ended September 30, 2026.
  • The company's name changed from Shukra Pharmaceuticals Limited to Shukra Medtech Limited on October 12, 2026.
  • Medtech segment commenced operations from October 1, 2025, contributing to segment revenue.
🔢 Key Numbers - exact figures from BSE filing, not rounded
Net Profit for the period (Q2 FY27)
Rs. 1,601.20 Lakhs
Revenue from Operations (Q2 FY27)
Rs. 4,220.38 Lakhs
Basic Earnings per Share (Q2 FY27)
Rs. 0.36
Total Assets (September 30, 2026)
Rs. 17,825.33 Lakhs
Total Equity (September 30, 2026)
Rs. 12,391.36 Lakhs
🏢 How This Affects the Company
📈
Business Impact
The company's strategic move into the Medtech segment, effective October 1, 2025, has introduced a new revenue stream, with the Medtech segment contributing Rs. 1,250.65 Lakhs in Q2 FY27.
💰
Financial Impact
Net profit for Q2 FY27 reached Rs. 1,601.20 Lakhs, alongside a revenue from operations of Rs. 4,220.38 Lakhs. Total assets increased to Rs. 17,825.33 Lakhs as of September 30, 2026, from Rs. 11,741.39 Lakhs on March 31, 2026.
⚙️
Operational Impact
The company now operates in two segments: Pharmaceutical and Medtech, indicating a diversification of its operational focus and business activities.
👥 What This Means For Shareholders
✅
Action Required
No action required based on this financial results filing.
👤
Who Is Affected
Shareholders of Shukra Pharmaceuticals Limited are now shareholders of Shukra Medtech Limited, following the name change effective October 12, 2026.
🔍
Management Signal
Management is signaling a strategic shift towards expanding into the Medtech sector and strengthening the company's capital base through warrant conversion.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List - track these upcoming events
Q3 FY27 financial results — assess sustained performance of both segments.
Updates on Medtech segment's revenue contribution and profitability.
Any further announcements regarding capital expenditure or strategic investments.
MEDIUM RISK Net cash from operations decreased and the Pharmaceutical segment's capital employed is negative.
💡 Investor Takeaway
Shukra Medtech (formerly Shukra Pharmaceuticals) reported Q2 FY27 standalone net profit of Rs. 1,601.20 Lakhs, a significant rise from Rs. 237.81 Lakhs in Q2 FY26. Revenue from operations for Q2 FY27 reached Rs. 4,220.38 Lakhs, compared to Rs. 587.74 Lakhs in Q2 FY26. The Medtech segment, operational since October 1, 2025, contributed to segment revenue.
⚖️ Strengths & Concerns

✅ Positives

  • Net Profit for Q2 FY27 stood at Rs. 1,601.20 Lakhs, showing substantial growth from Rs. 237.81 Lakhs in Q2 FY26.
  • Revenue from Operations for Q2 FY27 was Rs. 4,220.38 Lakhs, a significant increase from Rs. 587.74 Lakhs in Q2 FY26.

⚠️ Concerns

  • Net cash generated from operating activities for the half year ended September 30, 2026, was Rs. 149.35 Lakhs, a decrease from Rs. 301.83 Lakhs in the prior half year.
  • Capital Employed for the Pharmaceutical segment showed a negative value of (Rs. 4,202.50) Lakhs for the half year ended September 30, 2026.
📅 Company Track Record
Shukra Pharmaceuticals Ltd reported Q2 FY27 Net Profit of Rs. 1,601.20 Lakhs, a significant increase from Rs. 237.81 Lakhs in Q2 FY26. The company's name changed to Shukra Medtech Limited on October 12, 2026. Previously, the company had confirmed no deviation in its preferential issue fund utilization (May 2026) and reported FY26 Net Profit of Rs. 2,196.88 Lakhs.

Based on publicly available historical data. For context only.

❓ Frequently Asked Questions
What was Shukra Medtech's net profit in Q2 FY27?
Shukra Medtech reported a standalone net profit of Rs. 1,601.20 Lakhs for the quarter ended September 30, 2026 (Q2 FY27).
What was Shukra Medtech's revenue from operations for Q2 FY27?
Revenue from operations for Shukra Medtech stood at Rs. 4,220.38 Lakhs for the quarter ended September 30, 2026 (Q2 FY27).
What is the new name of Shukra Pharmaceuticals Limited and when was it effective?
The company's name changed from Shukra Pharmaceuticals Limited to Shukra Medtech Limited, effective from October 12, 2026.
When did the Medtech segment of Shukra Medtech begin contributing to revenue?
The Medtech segment of Shukra Medtech commenced operations and began contributing to segment revenue from October 1, 2025 onwards.

Questions based on this BSE filing only. For information purposes.

You've read one filing

There are 32,000 more, and one of them is about a company you own

Follow a company and we'll email you the moment it files again - explained, not just forwarded. Free.

  • Follow companies and get filings by email
  • Save any filing to read later
  • Two full AI analyses every month, free

No card needed. Sign in with Google in two taps.

⚠️ For Information Only - Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector - takes 5 seconds.